Benitec Biopharma Inc.
BNTC
$13.75
$0.1050.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 60.38% | 8.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 48.68% | 4.38% | |||
| Operating Income | -48.68% | -4.38% | |||
| Income Before Tax | -45.42% | -7.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -45.42% | -7.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -45.42% | -7.18% | |||
| EBIT | -48.68% | -4.38% | |||
| EBITDA | -49.08% | -4.42% | |||
| EPS Basic | 29.88% | 20.84% | |||
| Normalized Basic EPS | 29.87% | 10.46% | |||
| EPS Diluted | 29.88% | 20.84% | |||
| Normalized Diluted EPS | 29.87% | 10.46% | |||
| Average Basic Shares Outstanding | 107.39% | 19.70% | |||
| Average Diluted Shares Outstanding | 107.39% | 19.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||